Welcome to LookChem.com Sign In|Join Free

CAS

  • or

5241-64-5

Post Buying Request

5241-64-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5241-64-5 Usage

Chemical Properties

WHITE TO CREAM POWDER

Uses

Nα-Boc-D-tryptophan is an N-Boc-protected form of D-Tryptophan (T947205). D-Tryptophan is an unnatural isomer of L-Tryptophan (T947210) and is classified as an essential amino acid. D-Tryptophan has been synthesized as part of some potent Oxytocin (Acetate: O878500) antagonists that treat preterm labour.

Check Digit Verification of cas no

The CAS Registry Mumber 5241-64-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,2,4 and 1 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 5241-64:
(6*5)+(5*2)+(4*4)+(3*1)+(2*6)+(1*4)=75
75 % 10 = 5
So 5241-64-5 is a valid CAS Registry Number.
InChI:InChI=1/C16H20N2O4/c1-16(2,3)22-15(21)18-13(14(19)20)8-10-9-17-12-7-5-4-6-11(10)12/h4-7,9,13,17H,8H2,1-3H3,(H,18,21)(H,19,20)/p-1/t13-/m1/s1

5241-64-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (B2259)  N-(tert-Butoxycarbonyl)-D-tryptophan  >98.0%(HPLC)

  • 5241-64-5

  • 1g

  • 230.00CNY

  • Detail
  • TCI America

  • (B2259)  N-(tert-Butoxycarbonyl)-D-tryptophan  >98.0%(HPLC)

  • 5241-64-5

  • 5g

  • 790.00CNY

  • Detail
  • Alfa Aesar

  • (L09214)  N(alpha)-Boc-D-tryptophan, 97%   

  • 5241-64-5

  • 1g

  • 167.0CNY

  • Detail
  • Alfa Aesar

  • (L09214)  N(alpha)-Boc-D-tryptophan, 97%   

  • 5241-64-5

  • 5g

  • 437.0CNY

  • Detail
  • Aldrich

  • (15185)  Boc-D-Trp-OH  ≥98.0% (TLC)

  • 5241-64-5

  • 15185-5G

  • 608.40CNY

  • Detail

5241-64-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R)-3-(1H-indol-3-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid

1.2 Other means of identification

Product number -
Other names N-(tert-Butoxycarbonyl)-D-tryptophan

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5241-64-5 SDS

5241-64-5Relevant articles and documents

A class of DL-tryptophan compounds, preparation method and applications thereof

-

Paragraph 0058-0061, (2020/06/17)

The invention provides a DL-tryptophan compound represented by a general formula I or a pharmaceutically acceptable salt thereof, a preparation method and applications thereof, especially applicationsin preparation of RANKL inhibitors. According to the DL-tryptophan compound or the pharmaceutically acceptable salt thereof, an OPG-RANKL-RANK signal system can be intervened by inhibiting the interaction of RANKL-RANK, and the activity of RANKL in osteoclast precursor cells is regulated and controlled, so that formation of osteoclasts is inhibited, and bone resorption is reduced; and the DL-tryptophan compound or the pharmaceutically acceptable salt thereof is expected to play a role in preventing and treating bone metabolic diseases, and brings good news to bone metabolic disease patients.

Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease

Chalupova, Katarina,Korabecny, Jan,Bartolini, Manuela,Monti, Barbara,Lamba, Doriano,Caliandro, Rosanna,Pesaresi, Alessandro,Brazzolotto, Xavier,Gastellier, Anne-Julie,Nachon, Florian,Pejchal, Jaroslav,Jarosova, Michaela,Hepnarova, Vendula,Jun, Daniel,Hrabinova, Martina,Dolezal, Rafael,Zdarova Karasova, Jana,Mzik, Martin,Kristofikova, Zdena,Misik, Jan,Muckova, Lubica,Jost, Petr,Soukup, Ondrej,Benkova, Marketa,Setnicka, Vladimir,Habartova, Lucie,Chvojkova, Marketa,Kleteckova, Lenka,Vales, Karel,Mezeiova, Eva,Uliassi, Elisa,Valis, Martin,Nepovimova, Eugenie,Bolognesi, Maria Laura,Kuca, Kamil

, p. 491 - 514 (2019/03/08)

A combination of tacrine and tryptophan led to the development of a new family of heterodimers as multi-target agents with potential to treat Alzheimer's disease. Based on the in vitro biological profile, compound S-K1035 was found to be the most potent inhibitor of human acetylcholinesterase (hAChE) and human butyrylcholinesterase (hBChE), demonstrating balanced IC50 values of 6.3 and 9.1 nM, respectively. For all the tacrine-tryptophan heterodimers, favorable inhibitory effect on hAChE as well as on hBChE was coined to the optimal spacer length ranging from five to eight carbon atoms between these two pharmacophores. S-K1035 also showed good ability to inhibit Aβ42 self-aggregation (58.6 ± 5.1% at 50 μM) as well as hAChE-induced Aβ40 aggregation (48.3 ± 6.3% at 100 μM). The X-ray crystallographic analysis of TcAChE in complex with S-K1035 pinpointed the utility of the hybridization strategy applied and the structures determined with the two K1035 enantiomers in complex with hBChE could explain the higher inhibition potency of S-K1035. Other in vitro evaluations predicted the ability of S-K1035 to cross blood-brain barrier and to exert a moderate inhibition potency against neuronal nitric oxide synthase. Based on the initial promising biochemical data and a safer in vivo toxicity compared to tacrine, S-K1035 was administered to scopolamine-treated rats being able to dose-dependently revert amnesia.

Amino acid conjugated antimicrobial drugs: Synthesis, lipophilicity- activity relationship, antibacterial and urease inhibition activity

Ullah, Atta,Iftikhar, Fatima,Arfan, Muhammad,Batool Kazmi, Syeda Tayyaba,Anjum, Muhammad Naveed,Haq, Ihsan-ul,Ayaz, Muhammad,Farooq, Sadia,Rashid, Umer

, p. 140 - 153 (2018/01/10)

Present work describes the in vitro antibacterial evaluation of some new amino acid conjugated antimicrobial drugs. Structural modification was attempted on the three existing antimicrobial pharmaceuticals namely trimethoprim, metronidazole, isoniazid. Twenty one compounds from seven series of conjugates of these drugs were synthesized by coupling with some selected Boc-protected amino acids. The effect of structural features and lipophilicity on the antibacterial activity was investigated. The synthesized compounds were evaluated against five standard American type culture collection (ATCC) i.e. Staphylococcus aureus, Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa and Salmonella typhi strains of bacteria. Our results identified a close relationship between the lipophilicity and the activity. Triazine skeleton proved beneficial for the increase in hydrophobicity and potency. Compounds with greater hydrophobicity have shown excellent activities against Gram-negative strains of bacteria than Gram-positive. 4-amino unsubstituted trimethoprim-triazine derivative 7b have shown superior activity with MIC = 3.4 μM (2 μg/mL) for S. aureus and 1.1 μM (0.66 μg/mL) for E. coli. The synthesized compounds were also evaluated for their urease inhibition study. Microbial urease from Bacillus pasteurii was chosen for this study. Triazine derivative 7a showed excellent inhibition with IC50 = 6.23 ± 0.09 μM. Docking studies on the crystal structure of B. pasteurii urease (PDB ID 4UBP) were carried out.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 5241-64-5